Catriona Yale, Chief Development Officer at Akero Therapeutics, Inc. (AKRO), sold 2,825 shares at $22.64 ($64K) on 2024-06-11, disclosed to the SEC on 2024-06-13.
Open-market sale of $64k AKRO by Chief Development Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| AKRO | SELL | 2025-06-20 | $876K | — | Filing → |
| AKRO | SELL | 2025-06-20 | $179K | — | Filing → |
| AKRO | SELL | 2025-06-12 | $151K | — | Filing → |